Prostate cancer is one of the most common cancers in men, affecting millions globally. However, while many patients with prostate cancer respond to initial treatments, a significant portion will eventually develop castrate-resistant prostate cancer (CRPC). CRPC is a particularly aggressive and challenging form of prostate cancer that continues to progress despite the lowering of testosterone … Read more
Disclaimer:
We do not claim ownership of any content, links or images featured on this post unless explicitly stated. If you believe any content or images infringes on your copyright, please contact us immediately for removal (info@frobyn.com). Please note that content published under our account may be sponsored or contributed by guest authors. We assume no responsibility for the accuracy or originality of such content. We hold no responsibility for content and images published as ours is a publishers platform. Mail us for any query and we will remove that content/image immediately.